Skip to content

The need for comparison of oral food challenge outcome: the ALlergy Diagnosed by Open oR DOuble blind food challenge (ALDORADO) trial

The need for comparison of oral food challenge outcome: the ALlergy Diagnosed by Open oR DOuble blind food challenge (ALDORADO) trial - ALDORADO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50961
Enrollment
75
Registered
2021-05-26
Start date
2021-11-03
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Participants will undergo both challenges for the specific potential food allergen. As patients and/or their parents might be reluctant to perform a second test if symptoms occurred during the first

Sponsors

Martini Ziekenhuis
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children from four till eighteen years old for whom it is recommended to perform an OFC for a suspected food allergy for cashew nut, hazelnut or peanut will be eligible for inclusion.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they use beta blockers and/or prednisolone, if they suffer from uncontrolled asthma, unstable angina pectoris, fever or if the patient reported to be pregnant. Patients should also be able to adequately report the occurrence of possible symptoms and will be excluded if they are not able to do so (e.g. mentally disabled or not native Dutch speaker).

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be the difference in the proportion of positive outcomes of the DBPCFC and the open food challenge. Children who had a positive DBPCFC outcome but are not willing to perform the open food challenge will also be defined as a positive open food challenge.

Secondary

MeasureTime frame
The following secondary outcome measures will be analysed: eliciting dose (i.e. first dose that causes allergic symptoms) and stopping dose (i.e. cumulative total dose that has been eaten), occurrence of symptoms on all challenge days (objective, subjective and severity), percentage of false positive reactions (i.e. the occurrence of allergic symptoms on placebo day in case of DBPCFC) and percentage of successful introduction into diet (if OFC outcome is negative). Furthermore, we keep record of patients for whom an open food challenge might be indicated as first choice to investigate the added value of DBPCFC in these patients.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)